Managing cardiovascular risk in type 2 diabetes: what do the cardiovascular outcome trials mean for Australian practice?

Deed, Gary, Atherton, John J., d'Emden, Michael, Rasalam, Roy, Sharma, Anita, and Sindone, Andrew (2019) Managing cardiovascular risk in type 2 diabetes: what do the cardiovascular outcome trials mean for Australian practice? Diabetes Therapy, 10 (5). pp. 1625-1643.

[img]
Preview
PDF (Published Version) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (670kB) | Preview
View at Publisher Website: https://doi.org/10.1007/s13300-019-0663-...
 
38


Abstract

Understanding the implications of cardiovascular (CV) outcomes data of glucose-lowering agents on the management of type 2 diabetes mellitus can be challenging for many primary practitioners. Amongst different classes of diabetes medications assessed for CV safety, several agents within the sodium-glucose transport protein-2 inhibitor and glucagon-like peptide-1 receptor agonists classes have demonstrated CV risk reduction. Applying the trial findings to patients typically seen in clinical practice, such as those with established CV disease and those with multiple CV risk factors without established CV disease, requires further clarity. To bridge this gap in our current knowledge, the aim of this review was to utilise expert-driven opinions on common case scenarios and practical recommendations on the most appropriate choice of agents, according to an individual patient's clinical risk profile (CV and kidney disease), treatment preference and reimbursement environment from an Australian perspective.

Item ID: 60688
Item Type: Article (Research - C1)
ISSN: 1869-6951
Keywords: Cardiovascular, DPP-IV inhibitor, GLP-1RAs, Hospitalisation, Kidney, MACE, Management, Outcome, Risk, SGLT-2 inhibitors, Type 2 diabetes
Additional Information:

© The Author(s) 2019. This article is published under an open access license.

Funders: Boehringer Ingelheim Australia
Date Deposited: 23 Oct 2019 07:36
FoR Codes: 11 MEDICAL AND HEALTH SCIENCES > 1102 Cardiovascular Medicine and Haematology > 110201 Cardiology (incl Cardiovascular Diseases) @ 50%
11 MEDICAL AND HEALTH SCIENCES > 1103 Clinical Sciences > 110306 Endocrinology @ 50%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 50%
92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920104 Diabetes @ 50%
Downloads: Total: 38
Last 12 Months: 17
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page